Neurocrine Biosciences CEO receives 614 vested shares

The award schedule lists 614 shares vesting on November 1, 2027 and 614 shares on November 1, 2028, subject to its terms and conditions.

Available on EDGAR 11/03/2026 - 06:00 PM EST Accepted by SEC EDGAR 11/03/2026 - 05:59 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Neurocrine Biosciences (NBIX) CEO Kyle Gano converted 614 restricted stock units into 614 common shares on November 1, 2026. The company withheld 332 shares to satisfy tax withholding requirements on vesting; its footnote states no shares were sold. The reported RSU balance after vesting was 1,228 units.

Insider Trade Summary

614 shares exercised/converted

Exercise 3 txns

Insider Gano Kyle

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F2, F3	614	$0.00	$0.00
Exercise	Common Stock	614	$0.00	$0.00
Tax Withholding	Common Stock F1	332	$146.10	$49K

Holdings After Transaction: Restricted Stock Unit — 1,228 contracts (Direct); Common Stock — 155,010 shares (Direct)

Footnotes (3)

1. F1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
3. F3. This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, vested as to 614 shares on November 1, 2026 and will vest as to 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.

Key Figures

Common shares acquired: 614 shares Shares withheld: 332 shares Reported RSU balance: 1,228 RSUs +2 more

5 metrics

Common shares acquired 614 shares Received on November 1, 2026, upon RSU vesting

Shares withheld 332 shares Withheld on November 1, 2026, for tax withholding requirements

Reported RSU balance 1,228 RSUs Following the November 1, 2026 transaction

Scheduled RSU vesting 614 shares Scheduled for November 1, 2027, subject to award terms and conditions

Scheduled RSU vesting 614 shares Scheduled for November 1, 2028, subject to award terms and conditions

Key Terms

restricted stock units, contingent right, tax withholding requirements

3 terms

restricted stock units financial

"on vesting of restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one share"

tax withholding requirements financial

"to satisfy tax withholding requirements on vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NBIX shares did CEO Kyle Gano acquire from RSU vesting?

Kyle Gano received 614 common shares when 614 restricted stock units vested on November 1, 2026. The award terms state that each RSU represents a contingent right to receive one common share.

How many shares were withheld from Kyle Gano's NBIX RSUs?

Neurocrine Biosciences withheld 332 shares on November 1, 2026, to satisfy tax withholding requirements on the RSU vesting. The footnote states that no shares were sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gano Kyle

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/01/2026		M		614	A	$0	155,342	D
Common Stock	11/01/2026		F		332(1)	D	$146.1	155,010	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	11/01/2026		M			614	(3)	(3)	Common Stock	614	$0	1,228	D

Explanation of Responses:

1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

3. This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, vested as to 614 shares on November 1, 2026 and will vest as to 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)